Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Bladder Cancer, October 2021

Free Subscription


Abstracts

Retrieve all available abstracts of the following 185 articles:
HTML format


 

Single Articles

  1. WANG F, Zhang Y, Zhou X, Chen X, et al
    Circular RNA CircPPP1CB Suppresses Tumorigenesis by Interacting With the MiR-1307-3p/SMG1 Axis in Human Bladder Cancer.
    Front Cell Dev Biol. 2021;9:704683.
    PubMed    
    Abstract available

  2. ROUMIGUIE M, Black PC
    Sequential Gemcitabine plus Docetaxel Is the Standard Second-line Intravesical Therapy for BCG-unresponsive Non-muscle-invasive bladder cancer: Pro.
    Eur Urol Focus. 2021 Sep 27. pii: S2405-4569(21)00234.
    PubMed    
    Abstract available

  3. SINGH AK, Srikrishna G, Bivalacqua TJ, Bishai WR, et al
    Recombinant BCGs for tuberculosis and bladder cancer.
    Vaccine. 2021 Sep 27. pii: S0264-410X(21)01231.
    PubMed    
    Abstract available

  4. ZHI Y, Sun F, Cai C, Li H, et al
    LINC00265 promotes the viability, proliferation, and migration of bladder cancer cells via the miR-4677-3p/FGF6 axis.
    Hum Exp Toxicol. 2021 Sep 30:9603271211043479. doi: 10.1177/09603271211043479.
    PubMed    
    Abstract available

  5. TENNINGE S, Mogos H, Eriksson E, Netterling H, et al
    Control computerized tomography in neoadjuvant chemotherapy for muscle invasive urinary bladder cancer, has no value for treatment decisions and low correlation with nodal status.
    Scand J Urol. 2021 Sep 30:1-6. doi: 10.1080/21681805.2021.1981996.
    PubMed    
    Abstract available

  6. KITAGAWA K, Tatsumi M, Kato M, Komai S, et al
    An oral cancer vaccine using a Bifidobacterium vector suppresses tumor growth in a syngeneic mouse bladder cancer model.
    Mol Ther Oncolytics. 2021;22:592-603.
    PubMed    
    Abstract available

  7. YERGIN CG, Pafford R, Pirris J, Rao D, et al
    Spinal Tuberculosis Secondary to Intravesical Bacille Calmette-Guerin Treatment for Bladder Cancer.
    Cureus. 2021;13:e17446.
    PubMed    
    Abstract available

  8. YIN Y, Fan Y, Yu G, Du Y, et al
    LAPTM4B promotes the progression of bladder cancer by stimulating cell proliferation and invasion.
    Oncol Lett. 2021;22:765.
    PubMed    
    Abstract available

  9. HE Y, Wu Y, Liu Z, Li B, et al
    Identification of Signature Genes Associated With Invasiveness and the Construction of a Prognostic Model That Predicts the Overall Survival of Bladder Cancer.
    Front Genet. 2021;12:694777.
    PubMed    
    Abstract available

  10. CAO C, Yao L, Li A, Zhang Q, et al
    A CRISPR/dCasX-mediated transcriptional programming system for inhibiting the progression of bladder cancer cells by repressing c-MYC or activating TP53.
    Clin Transl Med. 2021;11:e537.
    PubMed    


  11. DONG Y, Zhang T, Li X, Yu F, et al
    Urine Biomarkers for the Diagnosis of Bladder Cancer: a Network Meta-Analysis.
    Urol J. 2021 Sep 29. pii: 6254. doi: 10.22037/uj.v18i.6254.
    PubMed    
    Abstract available

  12. VAN HOOGSTRATEN LMC, van Gennep EJ, Kiemeney LALM, Witjes JA, et al
    Occult lymph node metastases in patients without residual muscle-invasive bladder cancer at radical cystectomy with or without neoadjuvant chemotherapy: a nationwide study of 5417 patients.
    World J Urol. 2021 Sep 28. pii: 10.1007/s00345-021-03839.
    PubMed    
    Abstract available

  13. CHANG YH, Lin PH, Chen CC, Weng WH, et al
    Gain of TPPP as a predictor of progression in patients with bladder cancer.
    Exp Ther Med. 2021;22:1204.
    PubMed    
    Abstract available

  14. HE X, Xiao H, Yang R, Chen H, et al
    lncRNA LOC339524 inhibits the proliferation of bladder cancer cells by targeting the miR-875-5p/COPS7A signaling axis.
    Exp Ther Med. 2021;22:1202.
    PubMed    
    Abstract available

  15. CHEONG JK, Popov V, Alchera E, Locatelli I, et al
    A numerical study to investigate the effects of tumour position on the treatment of bladder cancer in mice using gold nanorods assisted photothermal ablation.
    Comput Biol Med. 2021;138:104881.
    PubMed    
    Abstract available

  16. STRINGER L, Ly TL, Moreno NV, Hewitt C, et al
    Assessing geographic and industry-related trends in bladder cancer in Ontario: A population-based study.
    Can Urol Assoc J. 2021 Sep 24. pii: cuaj.7263. doi: 10.5489/cuaj.7263.
    PubMed    
    Abstract available

  17. HYLDGAARD JM, Jensen JB
    The Inequality of Females in Bladder Cancer.
    APMIS. 2021 Sep 28. doi: 10.1111/apm.13183.
    PubMed    
    Abstract available

  18. BRUMMELHUIS ISG, Simons M, Lindner LH, Kort S, et al
    DPPG2-based thermosensitive liposomes as drug delivery system for effective muscle-invasive bladder cancer treatment in vivo.
    Int J Hyperthermia. 2021;38:1415-1424.
    PubMed    
    Abstract available

  19. CHENG X, Zhou X, Yi M, Xu S, et al
    Preoperative aspartate transaminase/alanine transaminase ratio as a prognostic biomarker in primary non-muscle-invasive bladder cancer: a propensity score-matched study.
    BMC Urol. 2021;21:136.
    PubMed    
    Abstract available

  20. GOMEZ BB, Lopez-Cortes R, Casas-Nebra FJ, Vazquez-Estevez S, et al
    Detection of Circulating Serum Protein Biomarkers of Non-Muscle Invasive Bladder Cancer after Protein Corona-Silver Nanoparticles Analysis by SWATH-MS.
    Nanomaterials (Basel). 2021;11.
    PubMed    
    Abstract available

  21. LIU YH, Chou MH, Meng E, Kao CC, et al
    A Rare Case Report of Metastatic Urothelial Carcinoma to Skull with Significant Reossification after Pembrolizumab.
    Medicina (Kaunas). 2021;57.
    PubMed    
    Abstract available

  22. TERAMOTO Y, Jiang G, Goto T, Mizushima T, et al
    Androgen Receptor Signaling Induces Cisplatin Resistance via Down-Regulating GULP1 Expression in Bladder Cancer.
    Int J Mol Sci. 2021;22.
    PubMed    
    Abstract available

  23. LI YR, Liu CH, Sun WC, Fan PY, et al
    The Risk of Bladder Cancer in Type 2 Diabetes Mellitus with Combination Therapy of SGLT-2 Inhibitors and Pioglitazone.
    J Pers Med. 2021;11.
    PubMed    
    Abstract available

  24. MENILLI L, Monteiro AR, Lazzarotto S, Morais FMP, et al
    Graphene Oxide and Graphene Quantum Dots as Delivery Systems of Cationic Porphyrins: Photo-Antiproliferative Activity Evaluation towards T24 Human Bladder Cancer Cells.
    Pharmaceutics. 2021;13.
    PubMed    
    Abstract available

  25. CHEN S, Deng C, Zheng W, Li S, et al
    Cannabidiol Effectively Promoted Cell Death in Bladder Cancer and the Improved Intravesical Adhesion Drugs Delivery Strategy Could Be Better Used for Treatment.
    Pharmaceutics. 2021;13.
    PubMed    
    Abstract available

  26. MANAN FAA, Yusof NA, Abdullah J, Mohammad F, et al
    Drug Release Profiles of Mitomycin C Encapsulated Quantum Dots-Chitosan Nanocarrier System for the Possible Treatment of Non-Muscle Invasive Bladder Cancer.
    Pharmaceutics. 2021;13.
    PubMed    
    Abstract available

  27. LEE J, Choo MS, Yoo S, Cho MC, et al
    Intravesical Prostatic Protrusion and Prognosis of Non-Muscle Invasive Bladder Cancer: Analysis of Long-Term Data over 5 Years with Machine-Learning Algorithms.
    J Clin Med. 2021;10.
    PubMed    
    Abstract available

  28. LEBLOND MM, Zdimerova H, Desponds E, Verdeil G, et al
    Tumor-Associated Macrophages in Bladder Cancer: Biological Role, Impact on Therapeutic Response and Perspectives for Immunotherapy.
    Cancers (Basel). 2021;13.
    PubMed    
    Abstract available

  29. YOU C, Piao XM, Kang K, Kim YJ, et al
    Integrative Transcriptome Profiling Reveals SKA3 as a Novel Prognostic Marker in Non-Muscle Invasive Bladder Cancer.
    Cancers (Basel). 2021;13.
    PubMed    
    Abstract available

  30. SUN K, Wang D, Yang BB, Ma J, et al
    The Emerging Functions of Circular RNAs in Bladder Cancer.
    Cancers (Basel). 2021;13.
    PubMed    
    Abstract available

  31. CANTO E, Faba OR, Zamora C, Mulet M, et al
    Immunological Status of Bladder Cancer Patients Based on Urine Leukocyte Composition at Radical Cystectomy.
    Biomedicines. 2021;9.
    PubMed    
    Abstract available

  32. FERRO M, Caputo VF, Barone B, Imbimbo C, et al
    Lymphocyte to Monocyte Ratio: A New Independent Prognostic Factor in Bladder Cancer Progression?
    Front Oncol. 2021;11:754649.
    PubMed    


  33. WANG Y, Gao J, Hu S, Zeng W, et al
    SLC25A21 Suppresses Cell Growth in Bladder Cancer via an Oxidative Stress-Mediated Mechanism.
    Front Oncol. 2021;11:682710.
    PubMed    
    Abstract available

  34. GUAN Y, Zhang G, Li Z, Ai X, et al
    Diagnostic and prognostic potentials of AK126393 in bladder cancer.
    J BUON. 2021;26:1504-1508.
    PubMed    
    Abstract available

  35. LI P, Yu Y, Wang X, Hu K, et al
    Biological functions of miR-363-3p/BTG2 in the metastasis of bladder cancer.
    J BUON. 2021;26:1498-1503.
    PubMed    
    Abstract available

  36. LIU F, Wang N, Wei J, Xue M, et al
    Circ_0006948 drives the malignant development of bladder cancer via activating the epithelial-mesenchymal transition.
    J BUON. 2021;26:1491-1497.
    PubMed    
    Abstract available

  37. LEE S, Ku JY, Kang BJ, Kim KH, et al
    A Unique Urinary Metabolic Feature for the Determination of Bladder Cancer, Prostate Cancer, and Renal Cell Carcinoma.
    Metabolites. 2021;11.
    PubMed    
    Abstract available

  38. YU K, Liu M, Huang Y, Yu Q, et al
    circMBOAT2 serves as the sponge of miR-433-3p to promote the progression of bladder cancer.
    Pathol Res Pract. 2021;227:153613.
    PubMed    
    Abstract available

  39. AKAN S, Ediz C
    A rare association in a patient with non-muscle invasive bladder cancer: ureteral fibroepithelial polyp and ipsilateral renal cell carcinoma: a case report.
    J Med Case Rep. 2021;15:475.
    PubMed    
    Abstract available

  40. CROCETTO F, Cimmino A, Ferro M, Terracciano D, et al
    Circulating tumor cells in bladder cancer: a new horizon of liquid biopsy for precision medicine.
    J Basic Clin Physiol Pharmacol. 2021 Sep 27. pii: jbcpp-2021-0233.
    PubMed    


  41. ARTHUSO FZ, Fairey AS, Boule NG, Courneya KS, et al
    Bladder cancer and exeRcise trAining during intraVesical thErapy-the BRAVE trial: a study protocol for a prospective, single-centre, phase II randomised controlled trial.
    BMJ Open. 2021;11:e055782.
    PubMed    
    Abstract available

  42. CAMPAGNA R, Pozzi V, Spinelli G, Sartini D, et al
    The Utility of Nicotinamide N-Methyltransferase as a Potential Biomarker to Predict the Oncological Outcomes for Urological Cancers: An Update.
    Biomolecules. 2021;11.
    PubMed    
    Abstract available

  43. OLLIVIER L, Guimas V, Rio E, Vaugier L, et al
    [Combination radiotherapy-immunotherapy in genitourinary cancer].
    Cancer Radiother. 2021;25.
    PubMed    
    Abstract available

  44. ELUMALAI T, Periasamy K, Rajendran I, Yedala A, et al
    A Systematic Review of Radiation-Related Lymphopenia in Genito-urinary Malignancies.
    Cancer Invest. 2021;39:769-776.
    PubMed    
    Abstract available

  45. YANG K, Yu W, Liu H, Ding F, et al
    Comparison of Genomic Characterization in Upper Tract Urothelial Carcinoma and Urothelial Carcinoma of the Bladder.
    Oncologist. 2021;26:e1395-e1405.
    PubMed    
    Abstract available

  46. LAVOIE JM, Sridhar SS, Ong M, North S, et al
    The Rapidly Evolving Landscape of First-Line Targeted Therapy in Metastatic Urothelial Cancer: A Systematic Review.
    Oncologist. 2021;26:e1381-e1394.
    PubMed    
    Abstract available

  47. VOLZ Y, Eismann L, Pfitzinger PL, Jokisch JF, et al
    Salvage cystectomy and ileal conduit urinary diversion as a last-line option for benign diseases-perioperative safety and postoperative health-related quality of life.
    Neurourol Urodyn. 2021;40:1154-1164.
    PubMed    
    Abstract available

  48. REYES-ARROYO J, Mejia-Rios LC, Fernandez-Vivar E, Gutierrez-Quiroz CT, et al
    Urachal adenocarcinoma. Analysis of 8 years in a third level medical facility.
    Cir Cir. 2021;89:71-76.
    PubMed    
    Abstract available

  49. HEPP Z, Shah SN, Smoyer K, Vadagam P, et al
    Epidemiology and treatment patterns for locally advanced or metastatic urothelial carcinoma: a systematic literature review and gap analysis.
    J Manag Care Spec Pharm. 2021;27:240-255.
    PubMed    
    Abstract available

  50. ITO Y, Ishida M, Ohe C, Miyasaka C, et al
    Signet-ring cell/histiocytoid carcinoma in the axilla: A case report with genetic analysis using next-generation sequencing.
    J Cutan Pathol. 2021;48:102-105.
    PubMed    
    Abstract available

  51. TOREN P, Brisson H, Simonyan D, Hovington H, et al
    Androgen receptor and immune cell PD-L1 expression in bladder tumors predicts disease recurrence and survival.
    World J Urol. 2021;39:1549-1558.
    PubMed    
    Abstract available

  52. MAGISTRO G, Zimmermann L, Bischoff R, Westhofen T, et al
    The natural course of urinalysis after urinary diversion.
    World J Urol. 2021;39:1559-1567.
    PubMed    
    Abstract available

  53. CHENG KW, Yip W, Shah A, Medina LG, et al
    Stoma complications and quality of life in patients with Indiana pouch versus appendico/neo-appendico-umbilicostomy urinary diversions.
    World J Urol. 2021;39:1521-1529.
    PubMed    
    Abstract available

  54. YANG D, Ma Y, Zhao P, Ma J, et al
    HMMR is a downstream target of FOXM1 in enhancing proliferation and partial epithelial-to-mesenchymal transition of bladder cancer cells.
    Exp Cell Res. 2021 Oct 5:112860. doi: 10.1016/j.yexcr.2021.112860.
    PubMed    
    Abstract available

  55. MEIJER RP
    Urothelial cancer organoids: a tool for bladder cancer research.
    Pathologe. 2021 Oct 8. pii: 10.1007/s00292-021-00988.
    PubMed    
    Abstract available

  56. BOBJER J, Hagberg O, Aljabery F, Gardmark T, et al
    Bladder cancer recurrence in papillary urothelial neoplasm of low malignant potential (PUNLMP) compared to G1 WHO 1999: a population-based study.
    Scand J Urol. 2021 Oct 8:1-5. doi: 10.1080/21681805.2021.1987980.
    PubMed    
    Abstract available

  57. ZHANG CM, Song LD, Wang JW, Ye HB, et al
    Role of miR-490-3p in blocking bladder cancer growth through targeting the RNA-binding protein PCBP2.
    Kaohsiung J Med Sci. 2021 Oct 7. doi: 10.1002/kjm2.12457.
    PubMed    
    Abstract available

  58. MI H, Bivalacqua TJ, Kates M, Seiler R, et al
    Predictive models of response to neoadjuvant chemotherapy in muscle-invasive bladder cancer using nuclear morphology and tissue architecture.
    Cell Rep Med. 2021;2:100382.
    PubMed    
    Abstract available

  59. REYES RM, Rios E, Barney S, Hugen CM, et al
    A Randomized Feasibility Trial Comparing Surveillance Regimens for Patients with Low and Low-Intermediate Risk Non-Muscle Invasive Bladder Cancer.
    Bladder Cancer. 2021;7:285-295.
    PubMed    
    Abstract available

  60. ZHANG YS, Li XJ, Zhang YH, Hu TC, et al
    Carbon ion radiotherapy for bladder cancer: A case report.
    World J Clin Cases. 2021;9:7833-7839.
    PubMed    
    Abstract available

  61. HORLEMANN B, Wurnschimmel C, Hoeh B, Sorce G, et al
    Radical Cystectomy vs. Radiotherapy in Urothelial Bladder Cancer in Elderly and Very Elderly Patients.
    Clin Genitourin Cancer. 2021 Sep 1. pii: S1558-7673(21)00160.
    PubMed    
    Abstract available

  62. LUO J, Xu J, Ou L, Zhou Y, et al
    Role of hypermethylated-lncRNAs in the prognosis of bladder cancer patients.
    J Int Med Res. 2021;49:3000605211049946.
    PubMed    
    Abstract available

  63. WANG H, Luo W, Wang X, Xue D, et al
    Testicular Nuclear Receptor 4 Regulates Proliferation and Apoptosis of Bladder Cancer via Bcl-2.
    Front Mol Biosci. 2021;8:670409.
    PubMed    
    Abstract available

  64. WANG K, Gu Y, Ni J, Zhang H, et al
    Combination of Total Psoas Index and Albumin-Globulin Score for the Prognosis Prediction of Bladder Cancer Patients After Radical Cystectomy: A Population-Based Study.
    Front Oncol. 2021;11:724536.
    PubMed    
    Abstract available

  65. RASTMANESH R
    Prediagnostic Serum 25-Hydroxyvitamin D and Mortality Among Bladder Cancer Patients in the Janus Serum Bank Cohort: A Short Comment [Letter].
    Clin Epidemiol. 2021;13:893-894.
    PubMed    


  66. SIRAB N, Drubay D, Maille P, Popova T, et al
    Multilayer spectrum of intratumoral heterogeneity in basal bladder cancer.
    J Pathol. 2021 Oct 6. doi: 10.1002/path.5813.
    PubMed    
    Abstract available

  67. ZHANG Y, Chen X, Lin J, Jin X, et al
    Biological functions and clinical significance of long noncoding RNAs in bladder cancer.
    Cell Death Discov. 2021;7:278.
    PubMed    
    Abstract available

  68. KIMURA S, Terada N, Otsuka I, Kimura T, et al
    [A Cohort Study on the Prognosis of Patients with Urothelial Carcinoma Using the Miyazaki Urological Cancer Database (MUCD)].
    Hinyokika Kiyo. 2021;67:407-412.
    PubMed    
    Abstract available

  69. JI N, Mukherjee N, Shu ZJ, Reyes RM, et al
    gammadelta T cells support antigen-specific alphabeta T cell-mediated antitumor responses during BCG treatment for bladder cancer.
    Cancer Immunol Res. 2021 Oct 4. pii: 2326-6066.CIR-21-0285.
    PubMed    
    Abstract available

  70. ADAMI BS, Diz FM, Oliveira Goncalves GP, Reghelin CK, et al
    Morphological and mechanical changes induced by quercetin in human T24 bladder cancer cells.
    Micron. 2021;151:103152.
    PubMed    
    Abstract available

  71. DRAGER DL
    [Perioperative nutritional interventions in patients undergoing radical cystectomy for bladder cancer].
    Urologe A. 2021 Oct 4. pii: 10.1007/s00120-021-01670.
    PubMed    


  72. SINGH MK, Jain M, Shyam H, Shankar P, et al
    Associated pathogenesis of bladder cancer and SARS-CoV-2 infection: a treatment strategy.
    Virusdisease. 2021 Sep 24:1-3. doi: 10.1007/s13337-021-00742.
    PubMed    
    Abstract available

  73. TAO H, Liao Y, Yan Y, He Z, et al
    BRCC3 Promotes Tumorigenesis of Bladder Cancer by Activating the NF-kappaB Signaling Pathway Through Targeting TRAF2.
    Front Cell Dev Biol. 2021;9:720349.
    PubMed    
    Abstract available

  74. ZHU H, Jia X, Wang Y, Song Z, et al
    M6A Classification Combined With Tumor Microenvironment Immune Characteristics Analysis of Bladder Cancer.
    Front Oncol. 2021;11:714267.
    PubMed    
    Abstract available

  75. LAO Y, Li X, He L, Guan X, et al
    Association Between Alcohol Consumption and Risk of Bladder Cancer: A Dose-Response Meta-Analysis of Prospective Cohort Studies.
    Front Oncol. 2021;11:696676.
    PubMed    
    Abstract available

  76. CHENG C, Qiu D, Chen J, Zu X, et al
    Efficacy of Intra-Arterial Plus Intravesical Chemotherapy for High-Risk Non-Muscle-Invasive Bladder Cancer: A Pooled Analysis.
    Front Pharmacol. 2021;12:707271.
    PubMed    
    Abstract available

  77. RHEA LP, Aragon-Ching JB
    Advances and Controversies With Checkpoint Inhibitors in Bladder Cancer.
    Clin Med Insights Oncol. 2021;15:11795549211044963.
    PubMed    
    Abstract available

  78. CULINE S, Harter V, Gravis G, Flechon A, et al
    Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial.
    Clin Genitourin Cancer. 2021 Sep 8. pii: S1558-7673(21)00162.
    PubMed    
    Abstract available

  79. CUI Y, Zhou T
    Diagnostic Value of Urinary MicroRNAs for Bladder Cancer in Asia.
    J Coll Physicians Surg Pak. 2021;31:1207-1213.
    PubMed    
    Abstract available

  80. XU Z, Zeng H, Liu Z, Jin K, et al
    Poor clinical outcomes and immunoevasive contexture in SIRPalpha(+) tumor-associated macrophages enriched muscle-invasive bladder cancer patients.
    Urol Oncol. 2021 Sep 30. pii: S1078-1439(21)00408.
    PubMed    
    Abstract available

  81. KOKSAL KARAYILDIRIM C, Nalbantsoy A, Karabay Yavasoglu NU
    Prunetin inhibits nitric oxide activity and induces apoptosis in urinary bladder cancer cells via CASP3 and TNF-alpha genes.
    Mol Biol Rep. 2021 Oct 2. pii: 10.1007/s11033-021-06719.
    PubMed    
    Abstract available

  82. KOUTROS S
    The need for, and challenges associated with, assessing occupational work histories for bladder and other occupational cancers.
    Occup Environ Med. 2021;78:623-624.
    PubMed    


  83. HAGHAYEGHI K, Lu S, Matoso A, Schiff SF, et al
    Association of current molecular subtypes in urothelial carcinoma with patterns of muscularis propria invasion.
    Virchows Arch. 2021;479:515-521.
    PubMed    
    Abstract available

  84. POWLES T, Assaf ZJ, Davarpanah N, Banchereau R, et al
    ctDNA guiding adjuvant immunotherapy in urothelial carcinoma.
    Nature. 2021;595:432-437.
    PubMed    
    Abstract available

  85. WANG G, Yuan R, Zhou C, Guo C, et al
    Urinary Large Cell Neuroendocrine Carcinoma: A Clinicopathologic Analysis of 22 Cases.
    Am J Surg Pathol. 2021;45:1399-1408.
    PubMed    
    Abstract available

  86. SINGH AK, Netea MG, Bishai WR
    BCG turns 100: its nontraditional uses against viruses, cancer, and immunologic diseases.
    J Clin Invest. 2021;131.
    PubMed    
    Abstract available

  87. EROL O, Ergul N, Algun Gedik A, Beyhan E, et al
    Synchronous Bilateral Adrenal Gland Metastases of Bladder Carcinoma Revealed on 18F-FDG PET/CT.
    Clin Nucl Med. 2021 Apr 21. pii: 00003072-900000000-96075.
    PubMed    
    Abstract available

  88. MOHAMMED AA, Elshentenawy A, Elsayed FM
    The effect of body mass index on clinico-pathological features and survival outcome in metastatic bladder carcinoma.
    Gulf J Oncolog. 2021;1:14-20.
    PubMed    
    Abstract available

  89. LIANG HZ, Zhao H, Gao J, Cao CF, et al
    Epirubicin-induced Kounis syndrome.
    BMC Cardiovasc Disord. 2021;21:133.
    PubMed    
    Abstract available

  90. EL-GEDAMY M, El-Khayat Z, Abol-Enein H, El-Said A, et al
    Rs-10889677 variant in interleukin-23 receptor may contribute to creating an inflammatory milieu more susceptible to bladder tumourigenesis: report and meta-analysis.
    Immunogenetics. 2021;73:207-226.
    PubMed    
    Abstract available

  91. DOS REIS PF, de Franca PS, Dos Santos MP, Martucci RB, et al
    Influence of nutritional status and frailty phenotype on health-related quality of life of patients with bladder or kidney cancer.
    Support Care Cancer. 2021;29:5139-5150.
    PubMed    
    Abstract available

  92. JOHNSON AL, Dozier BL, Colgin LMA
    Urothelial carcinoma in the urinary bladder of a Japanese macaque (Macaca fuscata).
    J Med Primatol. 2021;50:141-143.
    PubMed    
    Abstract available

  93. MCKENNEY JK
    Urothelial carcinoma in situ: diagnostic update.
    Pathology. 2021;53:86-95.
    PubMed    
    Abstract available

  94. SAMARATUNGA H, Delahunt B, Yaxley J, Egevad L, et al
    Tumour-like lesions of the urinary bladder.
    Pathology. 2021;53:44-55.
    PubMed    
    Abstract available

  95. TAKAHARA T, Murase Y, Tsuzuki T
    Urothelial carcinoma: variant histology, molecular subtyping, and immunophenotyping significant for treatment outcomes.
    Pathology. 2021;53:56-66.
    PubMed    
    Abstract available

  96. TZELVES L, Mourmouris P, Skolarikos A
    Does bipolar energy provide any advantage over monopolar surgery in transurethral resection of non-muscle invasive bladder tumors? A systematic review and meta-analysis.
    World J Urol. 2021;39:1093-1105.
    PubMed    
    Abstract available

  97. BENSON CR, Ajay D, Barrett-Harlow BL, Cunningham KG, et al
    Ureteroenteric anastomosis in orthotopic neobladder creation: do urinary tract infections impact stricture rate?
    World J Urol. 2020 May 28. pii: 10.1007/s00345-020-03266.
    PubMed    
    Abstract available

  98. ZHOU Q, Ding W, Qian Z, Zhu Q, et al
    Immunotherapy Strategy Targeting Programmed Cell Death Ligand 1 and CD73 with Macrophage-Derived Mimetic Nanovesicles to Treat Bladder Cancer.
    Mol Pharm. 2021 Oct 14. doi: 10.1021/acs.molpharmaceut.1c00448.
    PubMed    
    Abstract available

  99. RICHART L, Lapi E, Pancaldi V, Cuenca-Ardura M, et al
    STAG2 loss-of-function affects short-range genomic contacts and modulates the basal-luminal transcriptional program of bladder cancer cells.
    Nucleic Acids Res. 2021 Oct 14. pii: 6396892. doi: 10.1093.
    PubMed    
    Abstract available

  100. SUH J, Han D, Ku JH, Kim HH, et al
    Next-generation Proteomics-Based Discovery, Verification, and Validation of Urine Biomarkers for Bladder Cancer Diagnosis.
    Cancer Res Treat. 2021 Oct 9. pii: crt.2021.642. doi: 10.4143/crt.2021.
    PubMed    
    Abstract available

  101. FU J DR, Wang Y Dr
    Identification of a novel pyroptosis-related gene signature for predicting prognosis in bladder cancer.
    Cancer Invest. 2021 Oct 13:1-24. doi: 10.1080/07357907.2021.1991944.
    PubMed    
    Abstract available

  102. COMPERAT E
    Latest Developments and Current Problems in Bladder Cancer.
    World J Urol. 2021 Oct 13. pii: 10.1007/s00345-021-03857.
    PubMed    


  103. AZZI J, Waked A, Bou-Gharios J, Al Choboq J, et al
    Radiosensitizing Effect of Curcumin on Human Bladder Cancer Cell Lines: Impact on DNA Repair Mechanisms.
    Nutr Cancer. 2021 Oct 13:1-15. doi: 10.1080/01635581.2021.1985534.
    PubMed    
    Abstract available

  104. LI WJ, Li G, Liu ZW, Chen ZY, et al
    LncRNA LINC00355 promotes EMT and metastasis of bladder cancer cells through the miR-424-5p/HMGA2 axis.
    Neoplasma. 2021 Oct 11. pii: 210427N574. doi: 10.4149/neo_2021_210427.
    PubMed    
    Abstract available

  105. XIAO JF, Caliri AW, Duex JE, Theodorescu D, et al
    Targetable Pathways in Advanced Bladder Cancer: FGFR Signaling.
    Cancers (Basel). 2021;13.
    PubMed    
    Abstract available

  106. RUBIO-BRIONES J, Algaba F, Gallardo E, Marcos-Rodriguez JA, et al
    Recent Advances in the Management of Patients with Non-Muscle-Invasive Bladder Cancer Using a Multidisciplinary Approach: Practical Recommendations from the Spanish Oncology Genitourinary (SOGUG) Working Group.
    Cancers (Basel). 2021;13.
    PubMed    
    Abstract available

  107. XU G, Huang R, Xia W, Jiang B, et al
    Associations between inflammasome-related gene NLRP3 Polymorphisms (rs10754558 and rs35829419) and risk of bladder cancer in a Chinese population.
    J Clin Lab Anal. 2021 Oct 12:e23973. doi: 10.1002/jcla.23973.
    PubMed    
    Abstract available

  108. LIEDBERG F
    Personalized medicine for bladder cancer.
    Scand J Urol. 2021;55:419.
    PubMed    


  109. LI K, Li S, Tang S, Zhang M, et al
    KIF22 promotes bladder cancer progression by activating the expression of CDCA3.
    Int J Mol Med. 2021;48.
    PubMed    
    Abstract available

  110. LIU X, Liu S, Piao C, Zhang Z, et al
    Non-metabolic function of MTHFD2 activates CDK2 in bladder cancer.
    Cancer Sci. 2021 Oct 10. doi: 10.1111/cas.15159.
    PubMed    
    Abstract available

  111. ZHUANG C, Liu Y, Fu S, Yuan C, et al
    Corrigendum: Silencing of lncRNA MIR497HG via CRISPR/Cas13d Induces Bladder Cancer Progression Through Promoting the Crosstalk Between Hippo/Yap and TGF-beta/Smad Signaling.
    Front Mol Biosci. 2021;8:664616.
    PubMed    
    Abstract available

  112. VENKAT S, Khan AI, Taylor BL, Patel NA, et al
    Does neoadjuvant chemotherapy diminish the sex disparity in bladder cancer survival after radical cystectomy?
    Urol Oncol. 2021 Oct 7. pii: S1078-1439(21)00415.
    PubMed    
    Abstract available

  113. MUKHERJEE N, Julian E, Torrelles JB, Svatek RS, et al
    Effects of Mycobacterium bovis Calmette et Guerin (BCG) in oncotherapy: Bladder cancer and beyond.
    Vaccine. 2021 Oct 6. pii: S0264-410X(21)01256.
    PubMed    
    Abstract available

  114. CHUNG WM, Molony RD, Lee YF
    Non-stem bladder cancer cell-derived extracellular vesicles promote cancer stem cell survival in response to chemotherapy.
    Stem Cell Res Ther. 2021;12:533.
    PubMed    
    Abstract available

  115. YAN J, Yu W, Lu C, Liu C, et al
    High ORAI3 expression correlates with good prognosis in human muscle-invasive bladder cancer.
    Gene. 2021 Oct 6:145994. doi: 10.1016/j.gene.2021.145994.
    PubMed    
    Abstract available

  116. JOSSE PR, Koutros S, Tardon A, Rothman N, et al
    Adapting Decision Rules to Estimate Occupational Metalworking Fluid Exposure in a Case-Control Study of Bladder Cancer in Spain.
    Ann Work Expo Health. 2021 Oct 9. pii: 6384957. doi: 10.1093.
    PubMed    
    Abstract available

  117. NG CHIENG HIN J, Hettiarachchilage D, Gravestock P, Rai B, et al
    Role of Ureteroscopy in Treatment of Upper Tract Urothelial Carcinoma.
    Curr Urol Rep. 2021;22:49.
    PubMed    
    Abstract available

  118. COZZI G, Musi G, Milani M, Jemos C, et al
    Impact of Perioperative Immunonutrition on Complications in Patients Undergoing Radical Cystectomy: A Retrospective Analysis.
    Integr Cancer Ther. 2021;20:15347354211019483.
    PubMed    
    Abstract available

  119. JINDAL T, Dey D, Pawar P, Subedi N, et al
    Ureteric sarcomatoid urothelial carcinoma with chondrosarcomatous differentiation: A rare entity.
    Indian J Pathol Microbiol. 2021;64:418-419.
    PubMed    


  120. EBERHARD J, Hirsch D, Schilling O, Dirks WG, et al
    First report on establishment and characterization of a carcinosarcoma tumour cell line model of the bladder.
    Sci Rep. 2021;11:6030.
    PubMed    
    Abstract available

  121. GROSS JT, Vetter JM, Sands KG, Palka JK, et al
    Initial Experience with Single-Port Robot-Assisted Radical Cystectomy: Comparison of Perioperative Outcomes Between Single-Port and Conventional Multiport Approaches.
    J Endourol. 2021;35:1177-1183.
    PubMed    
    Abstract available

  122. MULAWKAR P, Sharma G, Garge P
    Evaluation of Spectra A and B Modes in Diagnosis of Suspicious Bladder Lesions.
    J Endourol. 2021;35:1184-1189.
    PubMed    
    Abstract available

  123. YOO Y, Choi E, Lee DH, Park S, et al
    Diagnostic value of urine cytology in detecting histologic variants of urothelial carcinomas in the urinary bladder: Cytopathologic correlation of 72 cases.
    Diagn Cytopathol. 2021;49:367-373.
    PubMed    
    Abstract available

  124. TANG Y, Kortum A, Vohra I, Schwarz RA, et al
    Initial Results of First In Vivo Imaging of Bladder Lesions Using a High-Resolution Confocal Microendoscope.
    J Endourol. 2021;35:1190-1197.
    PubMed    
    Abstract available

  125. HU H, Zhou H, Xu D
    A review of the effects and molecular mechanisms of dimethylcurcumin (ASC-J9) on androgen receptor-related diseases.
    Chem Biol Drug Des. 2021;97:821-835.
    PubMed    
    Abstract available

  126. TANNERU K, Jazayeri SB, Kumar J, Alam MU, et al
    Intracorporeal versus extracorporeal urinary diversion following robot-assisted radical cystectomy: a meta-analysis, cumulative analysis, and systematic review.
    J Robot Surg. 2021;15:321-333.
    PubMed    
    Abstract available

  127. HACIHASANOGLU E, YUcetaS U, OkCu O, BehzatoGlu K, et al
    Stromal Lymphoid Response Status in Micropapillary Urothelial Carcinomas Diagnosed in Bladder Transurethral Resections and its Comparison with Conventional Urothelial Carcinomas.
    Turk Patoloji Derg. 2021;37:26-31.
    PubMed    
    Abstract available

  128. ROCCO B, Luciani LG, Collins J, Sanchez-Salas R, et al
    Posterior reconstruction during robotic-assisted radical cystectomy with intracorporeal orthotopic ileal neobladder: description and outcomes of a simple step.
    J Robot Surg. 2021;15:355-361.
    PubMed    
    Abstract available

  129. GUPTA S, Dutta A, Pal DK
    Comparison of intravesical adjuvant therapy in bladder cancer with two different maintenance regimens of mitomycin and BCG.
    Urologia. 2021 Oct 20:3915603211050783. doi: 10.1177/03915603211050783.
    PubMed    
    Abstract available

  130. WANG X, Yu J, Chen J, Hou Y, et al
    Copy number variation analysis of m(6) A regulators identified METTL3 as a prognostic and immune-related biomarker in bladder cancer.
    Cancer Med. 2021 Oct 20. doi: 10.1002/cam4.3981.
    PubMed    
    Abstract available

  131. MA L, Zhang D, Huang Z, Zheng R, et al
    Functional variants of RPS6KB1 and PIK3R1 in the autophagy pathway genes and risk of bladder cancer.
    Arch Toxicol. 2021 Oct 19. pii: 10.1007/s00204-021-03173.
    PubMed    
    Abstract available

  132. MASON J, Hasnain Z, Miranda G, Gill K, et al
    Prediction of Metastatic Patterns in Bladder Cancer: Spatiotemporal Progression and Development of a Novel, Web-based Platform for Clinical Utility.
    Eur Urol Open Sci. 2021;32:8-18.
    PubMed    
    Abstract available

  133. IDE H, Kikuchi E, Ogihara K, Niwa N, et al
    Urinary pH is an independent predictor of upper tract recurrence in non-muscle-invasive bladder cancer patients with a smoking history.
    Sci Rep. 2021;11:20675.
    PubMed    
    Abstract available

  134. GAO Z, Wu D, Zheng W, Zhu T, et al
    Prognostic value of immune-related lncRNA pairs in patients with bladder cancer.
    World J Surg Oncol. 2021;19:304.
    PubMed    
    Abstract available

  135. MAO C, Xu X, Ding Y, Xu N, et al
    Optimization of BCG Therapy Targeting Neutrophil Extracellular Traps, Autophagy, and miRNAs in Bladder Cancer: Implications for Personalized Medicine.
    Front Med (Lausanne). 2021;8:735590.
    PubMed    
    Abstract available

  136. FAN B, Huang Y, Wen S, Teng Q, et al
    Predictive Value of Preoperative Positive Urine Cytology for Development of Bladder Cancer After Nephroureterectomy in Patients With Upper Urinary Tract Urothelial Carcinoma: A Prognostic Nomogram Based on a Retrospective Multicenter Cohort Study and
    Front Oncol. 2021;11:731318.
    PubMed    
    Abstract available

  137. MO L, Xu L, Jia M, Su B, et al
    Shikonin suppresses the epithelial-to-mesenchymal transition by downregulating NHE1 in bladder cancer cells.
    J Cancer. 2021;12:6814-6824.
    PubMed    
    Abstract available

  138. ANDERSEN CS, Thoft Jensen B, Nielsen Holck E, Kingo PS, et al
    Prospective versus retrospective recordings of comorbidities and complications in bladder cancer patients undergoing radical cystectomy - a randomized controlled trial.
    Scand J Urol. 2021 Oct 16:1-6. doi: 10.1080/21681805.2021.1987978.
    PubMed    
    Abstract available

  139. ZIETMAN AL
    Expression of Editorial Concern: Tunio MA, Hashmi A, Qayyum A, et al. Whole-pelvis or bladder-only chemoradiation for lymph node-negative invasive bladder cancer: Single-institution experience. Int J Radiat Oncol Biol Phys. 2012;82:e457-e462.
    Int J Radiat Oncol Biol Phys. 2021;111:1094.
    PubMed    


  140. CHUNG JW, Kim JW, Lee EH, Chun SY, et al
    Prognostic Significance of the Neutrophil-to-Lymphocyte Ratio in Patients with Non-Muscle Invasive Bladder Cancer treated with Intravesical Bacillus Calmette-Guerin and the Relationship with the CUETO Scoring Model.
    Urol J. 2021 Oct 16. pii: 6765. doi: 10.22037/uj.v18i.6765.
    PubMed    
    Abstract available

  141. PARTOVIPOUR E, Roshandel G, Motlagh A, Salavati F, et al
    Bladder Cancer Incidence in Iran: Results of the Iranian National Population-Based Cancer Registry from 2014 to 2016.
    Urol J. 2021 Oct 13. pii: 6760. doi: 10.22037/uj.v18i.6760.
    PubMed    
    Abstract available

  142. TAKAHARA K, Sumitomo M, Ito M, Ito F, et al
    Predictors of Secondary Bladder Cancer in Patients with Prostate Cancer Treated with Brachytherapy: A Single-institution Study of a Japanese Cohort.
    Urol J. 2021 Oct 13. pii: 6718. doi: 10.22037/uj.v18i.6718.
    PubMed    
    Abstract available

  143. VALLILAS C, Zachou M, Dolkiras P, Sakellariou S, et al
    Difficulties in Diagnosing and Treating Disseminated Bacillus Calmette-Guerin (BCG) Infection After Intravesical BCG Therapy in a Patient with Liver Cirrhosis: A Case Report.
    Am J Case Rep. 2021;22:e933006.
    PubMed    
    Abstract available

  144. VON LANDENBERG N, Benderska-Soder N, Bismarck E, Kernig K, et al
    [Rational follow-up of non-muscle invasive bladder cancer].
    Urologe A. 2021 Oct 15. pii: 10.1007/s00120-021-01683.
    PubMed    
    Abstract available

  145. GAKIS G
    [Prophylaxis of recurrence in low-to-intermediate risk non-muscle invasive bladder cancer (NMIBC)].
    Urologe A. 2021 Oct 15. pii: 10.1007/s00120-021-01680.
    PubMed    
    Abstract available

  146. SUGEETA SS, Sharma A, Ng K, Nayak A, et al
    Biomarkers in Bladder Cancer Surveillance.
    Front Surg. 2021;8:735868.
    PubMed    
    Abstract available

  147. LIN Y, Zhang Y, Luo L, Zhang X, et al
    Clinical effect of robot-assisted radical cystectomy in bladder cancer.
    Am J Transl Res. 2021;13:10545-10553.
    PubMed    
    Abstract available

  148. YI L, Wang H, Li W, Ye K, et al
    The FOXM1/RNF26/p57 axis regulates the cell cycle to promote the aggressiveness of bladder cancer.
    Cell Death Dis. 2021;12:944.
    PubMed    
    Abstract available

  149. WANG L, Jiang G, Jing N, Liu X, et al
    Downregulating testosterone levels enhance immunotherapy efficiency.
    Oncoimmunology. 2021;10:1981570.
    PubMed    
    Abstract available

  150. MAYER K, Briese W, Blieninger J, Brossart P, et al
    Development of Skin Rash Predicts Outcome of Anti-PD-1- and Anti-CTLA4-Based Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer or Squamous Cell Carcinoma of the Head and Neck: A Single-Center Analysis.
    Oncol Res Treat. 2021;44:538-546.
    PubMed    
    Abstract available

  151. JIN H, D'Urso V, Neuteboom B, McKenna SD, et al
    Avelumab internalization by human circulating immune cells is mediated by both Fc gamma receptor and PD-L1 binding.
    Oncoimmunology. 2021;10:1958590.
    PubMed    
    Abstract available

  152. XU Z, Zhu H, Wang H
    Segmentation of the urothelium in optical coherence tomography images with dynamic contrast.
    J Biomed Opt. 2021;26.
    PubMed    
    Abstract available

  153. HUH H, Lee SW, Cho JE, Kim HC, et al
    Effect of chlorpheniramine administration on postoperative catheter-related bladder discomfort in patients undergoing transurethral excision of bladder tumor: a prospective randomized study.
    J Anesth. 2021;35:646-653.
    PubMed    
    Abstract available

  154. KLORIN G, Halachmi S, Nativ O, Massalha Y, et al
    Morphometric analysis of nuclear symmetry in urothelial carcinoma for predicting tumor recurrence.
    Microsc Res Tech. 2021;84:2559-2564.
    PubMed    
    Abstract available

  155. CHAN KM, Gleadle J, Li J, Michl TD, et al
    Improving hexaminolevulinate enabled cancer cell detection in liquid biopsy immunosensors.
    Sci Rep. 2021;11:7283.
    PubMed    
    Abstract available

  156. CHOW PM, Chang YW, Kuo KL, Lin WC, et al
    CDK7 inhibition by THZ1 suppresses cancer stemness in both chemonaive and chemoresistant urothelial carcinoma via the hedgehog signaling pathway.
    Cancer Lett. 2021;507:70-79.
    PubMed    
    Abstract available

  157. GUPTA R, Epstein JI
    Plasma cell neoplasms of the bladder: a series of 9 cases.
    Hum Pathol. 2021;111:52-58.
    PubMed    
    Abstract available

  158. CE R, Lavayen V, Couto GK, De Marchi JGB, et al
    Folic Acid-Doxorubicin-Double-Functionalized-Lipid-Core Nanocapsules: Synthesis, Chemical Structure Elucidation, and Cytotoxicity Evaluation on Ovarian (OVCAR-3) and Bladder (T24) Cancer Cell Lines.
    Pharm Res. 2021;38:301-317.
    PubMed    
    Abstract available

  159. ZHANG M, Wang L, Yue Y, Zhang L, et al
    ITPR3 facilitates tumor growth, metastasis and stemness by inducing the NF-kB/CD44 pathway in urinary bladder carcinoma.
    J Exp Clin Cancer Res. 2021;40:65.
    PubMed    
    Abstract available

  160. YAN Q, Chen BJ, Hu S, Qi SL, et al
    Emerging role of RNF2 in cancer: From bench to bedside.
    J Cell Physiol. 2021;236:5453-5465.
    PubMed    
    Abstract available

  161. HUSSEIN S, Fathi A, Abouhashem NS, Amer S, et al
    SATB-1 and Her2 as predictive molecular and immunohistochemical markers for urothelial cell carcinoma of the bladder.
    Cancer Biomark. 2021;30:249-259.
    PubMed    
    Abstract available

  162. LEGGETT CS, Doll MA, States JC, Hein DW, et al
    Acetylation of putative arylamine and alkylaniline carcinogens in immortalized human fibroblasts transfected with rapid and slow acetylator N-acetyltransferase 2 haplotypes.
    Arch Toxicol. 2021;95:311-319.
    PubMed    
    Abstract available

  163. ROGERS JE, Ajani JA
    The role of ramucirumab and pembrolizumab combination in patients with advanced non-small cell lung cancer, gastroesophageal adenocarcinoma, or urothelial carcinoma.
    Chin Clin Oncol. 2021;10:30.
    PubMed    


  164. PAN Y, Hong YC, Hsiao CH, Shih HJ, et al
    Effects of Concurrent Chemoradiotherapy on the Metastasis and the Mesenchymal Transition of Bladder Urothelial Carcinoma Cells.
    Anticancer Res. 2021;41:4957-4968.
    PubMed    
    Abstract available

  165. SILVERS CR, Messing EM, Miyamoto H, Lee YF, et al
    Tenascin-C expression in the lymph node pre-metastatic niche in muscle-invasive bladder cancer.
    Br J Cancer. 2021 Sep 25. pii: 10.1038/s41416-021-01554.
    PubMed    
    Abstract available

  166. BARCLAY ME, Abel GA, Greenberg DC, Rous B, et al
    Socio-demographic variation in stage at diagnosis of breast, bladder, colon, endometrial, lung, melanoma, prostate, rectal, renal and ovarian cancer in England and its population impact.
    Br J Cancer. 2021 Feb 9. pii: 10.1038/s41416-021-01279.
    PubMed    
    Abstract available

  167. TEO MY, Al-Ahmadie H, Seier K, Tully C, et al
    Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma.
    Br J Cancer. 2021;124:1214-1221.
    PubMed    
    Abstract available

  168. BAART VM, van der Horst G, Deken MM, Bhairosingh SS, et al
    A multimodal molecular imaging approach targeting urokinase plasminogen activator receptor for the diagnosis, resection and surveillance of urothelial cell carcinoma.
    Eur J Cancer. 2021;146:11-20.
    PubMed    
    Abstract available

  169. ALFRED WITJES J
    Re: Five-factor Prognostic Model for Survival of Post-platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors.
    Eur Urol. 2021;80:113.
    PubMed    


  170. BEDKE J, Maas M
    Re: Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma.
    Eur Urol. 2021;80:257-258.
    PubMed    


  171. MASSON-LECOMTE A, Meria P
    Re: Complications Associated with Ureteroscopic Management of Upper Tract Urothelial Carcinoma.
    Eur Urol. 2021;80:255.
    PubMed    


  172. HARADA M, Tomisaki I, Minato A, Onishi R, et al
    Combination therapy with paclitaxel and gemcitabine after platinum-based chemotherapy in patients with advanced urothelial cancer.
    Int J Urol. 2021;28:970-974.
    PubMed    
    Abstract available

  173. NARITA T, Hatakeyama S, Numakura K, Kobayashi M, et al
    Comparison of pembrolizumab with conventional chemotherapy after first-line platinum-based chemotherapy for advanced urothelial carcinoma in real-world practice: A multicenter retrospective study.
    Int J Urol. 2021;28:899-905.
    PubMed    
    Abstract available

  174. CHAN EO, Chan VW, Poon JY, Chan BH, et al
    Clear cell carcinoma of the urinary bladder: a systematic review.
    Int Urol Nephrol. 2021;53:815-824.
    PubMed    
    Abstract available

  175. KHANNA A, Zganjar A, Lyon T, Shah P, et al
    A Contemporary Analysis of Urethral Recurrence following Radical Cystectomy.
    J Urol. 2021;206:970-977.
    PubMed    
    Abstract available

  176. LOTAN Y, de Jong J, Liu VYT, Bismar TA, et al
    Patients With Muscle Invasive Bladder Cancer with Non-luminal Subtype Derive Greatest Benefit from Platinum Based Neoadjuvant Chemotherapy.
    J Urol. 2021 Oct 13:101097JU0000000000002261. doi: 10.1097/JU.0000000000002261.
    PubMed    
    Abstract available

  177. CHEN X, Chen H, Yao H, Zhao K, et al
    Turning up the heat on non-immunoreactive tumors: pyroptosis influences the tumor immune microenvironment in bladder cancer.
    Oncogene. 2021 Sep 29. pii: 10.1038/s41388-021-02024.
    PubMed    
    Abstract available

  178. REN S, Zhang N, Shen L, Lu Y, et al
    Lnc00892 competes with c-Jun to block NCL transcription, reducing the stability of RhoA/RhoC mRNA and impairing bladder cancer invasion.
    Oncogene. 2021 Oct 6. pii: 10.1038/s41388-021-02033.
    PubMed    
    Abstract available

  179. SUI W, Hall ME, Barocas DA, Chang SS, et al
    Association between surgical volume and survival among patients with variant histologies of bladder cancer.
    Urology. 2021 Oct 1. pii: S0090-4295(21)00884.
    PubMed    
    Abstract available

  180. VERGHOTE F, Poppe L, Verbeke S, Dirix P, et al
    Evaluating the impact of 18F-FDG-PET-CT on risk stratification and treatment adaptation for patients with muscle-invasive bladder cancer (EFFORT-MIBC): a phase II prospective trial.
    BMC Cancer. 2021;21:1113.
    PubMed    
    Abstract available

  181. WANG M, Ren X, Wang G, Sun X, et al
    Construction of a survival prediction model for high-and low -grade UTUC after tumor resection based on "SEER database": a multicenter study.
    BMC Cancer. 2021;21:999.
    PubMed    
    Abstract available

  182. COLLING R, Colling H, Browning L, Verrill C, et al
    Validation of grading of non-invasive urothelial carcinoma by digital pathology for routine diagnosis.
    BMC Cancer. 2021;21:995.
    PubMed    
    Abstract available

  183. HEMMINKI K, Forsti A, Hemminki A, Ljungberg B, et al
    Incidence trends in bladder and lung cancers between Denmark, Finland and Sweden may implicate oral tobacco (snuff/snus) as a possible risk factor.
    BMC Cancer. 2021;21:604.
    PubMed    
    Abstract available

  184. GRIVAS P, Loriot Y, Morales-Barrera R, Teo MY, et al
    Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS).
    BMC Cancer. 2021;21:593.
    PubMed    
    Abstract available

  185. KLOSE K, Packeiser EM, Muller P, Granados-Soler JL, et al
    Metformin and sodium dichloroacetate effects on proliferation, apoptosis, and metabolic activity tested alone and in combination in a canine prostate and a bladder cancer cell line.
    PLoS One. 2021;16:e0257403.
    PubMed    
    Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design:


;